

IMS-IL-1 **Paradigm Shift in Drug Discovery & Development Model**

○Keiichi MASUYA¹

¹Chief Operating Officer of PeptiDream Inc.

From pharmaceutical market's point of view, low molecular pharmaceuticals historically accounted for the most, then antibody drugs that appeared about 20 years ago has been steadily growing, currently accounted for 1/8 of the whole of pharmaceutical market. Of course both advantages and disadvantages of above two areas are mostly known, therefore new conceptual approaches, new pharmaceuticals and innovative treatments/combinations which can cover remaining druggable space, historically undruggable space and unmet medical need are strongly desired. On the other hand, in order to meet the various requirements of a wide range of target protein in drug discovery research, for instance, new methodologies to replace historical HTS and new approaches to shortly create probe chemicals which can be used for biological validation of the target protein, particularly in the difficult target classes, have been required for a long time. In this lecture, I could introduce how our PDPS (Peptide Discovery Platform System) can contribute to the above proposition based on some cases.